Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma | Zendy

Yuan Zhang | Zendy; Lei Chen | Zendy; Guoqing Hu | Zendy; Ning Zhang | Zendy; Xiaodong Zhu | Zendy; Kunyu Yang | Zendy; Feng Jin | Zendy; Mei Shi | Zendy; YuPei Chen | Zendy; WeiHan Hu | Zendy; Zhibin Cheng | Zendy; Siyang Wang | Zendy; Ye Tian | Zendy; Xicheng Wang | Zendy; Yan Sun | Zendy; Jingao Li | Zendy; WenFei Li | Zendy; YuHong Li | Zendy; LingLong Tang | Zendy; YanPing Mao | Zendy; GuanQun Zhou | Zendy; Rui Sun | Zendy; Xu Liu | Zendy; Rui Guo | Zendy; Guoxian Long | Zendy; Shaoqiang Liang | Zendy; Ling Li | Zendy; Jing Huang | Zendy; Jinhua Long | Zendy; Jian Zang | Zendy; Qiaodan Liu | Zendy; Li Zou | Zendy; Qiong-Fei Su | Zendy; Baomin Zheng | Zendy; Yun Xiao | Zendy; Ying Guo | Zendy; Fei Han | Zendy; HaoYuan Mo | Zendy; JiaWei Lv | Zendy; Xiaojing Du | Zendy; Cheng Xu | Zendy; Na Liu | Zendy; YingQin Li | Zendy; Melvin L.K. Chua | Zendy; FangYun Xie | Zendy; Ying Sun | Zendy; Jun Ma | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma

Author(s) -

Yuan Zhang,

Lei Chen,

Guoqing Hu,

Ning Zhang,

Xiaodong Zhu,

Kunyu Yang,

Feng Jin,

Mei Shi,

YuPei Chen,

WeiHan Hu,

Zhibin Cheng,

Siyang Wang,

Ye Tian,

Xicheng Wang,

Yan Sun,

Jingao Li,

WenFei Li,

YuHong Li,

LingLong Tang,

YanPing Mao,

GuanQun Zhou,

Rui Sun,

Xu Liu,

Rui Guo,

Guoxian Long,

Shaoqiang Liang,

Ling Li,

Jing Huang,

Jinhua Long,

Jian Zang,

Qiaodan Liu,

Li Zou,

Qiong-Fei Su,

Baomin Zheng,

Yun Xiao,

Ying Guo,

Fei Han,

HaoYuan Mo,

JiaWei Lv,

Xiaojing Du,

Cheng Xu,

Na Liu,

YingQin Li,

Melvin L.K. Chua,

FangYun Xie,

Ying Sun,

Jun Ma

Publication year - 2019

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1905287

Subject(s) - medicine , gemcitabine , induction chemotherapy , chemoradiotherapy , hazard ratio , oncology , cisplatin , chemotherapy , population , nasopharyngeal carcinoma , radiation therapy , clinical endpoint , surgery , confidence interval , randomized controlled trial , environmental health

Platinum-based concurrent chemoradiotherapy is the standard of care for patients with locoregionally advanced nasopharyngeal carcinoma. Additional gemcitabine and cisplatin induction chemotherapy has shown promising efficacy in phase 2 trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research